Therefore, they are generally open to discussing alternative options that may better align with your health goals and personal comfort
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
M., Deanfield, J., Erdmann, E., Holman, R
There is limited data that shows how different active ingredients, or the alternative doses offered by compounding pharmacies, may change the effects of GLP-1s
Common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort
Who May Benefit from Dual-Action Therapy Versus GLP-1 Monotherapy Dual-agonist therapy may be appropriate for patients with type 2 diabetes, prediabetes, or obesity who have inadequate response to GLP-1 monotherapy or require more aggressive metabolic intervention